NovImmune SA-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:NovImmune SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013969
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
NovImmune SA (NovImmune) is a biopharmaceutical company that discovers and develops antibody-based drugs for the treatment of inflammatory diseases, immune-related disorders and cancer. The company develops pipeline products using its proprietary mAb generating platform, DiversityTrap and kappa-lambda bispecific antibody platform. Its pipeline products include Emapalumab, a human anti-IFN? monoclonal antibody used for the treatment of Hemophagocytic Lymphohistiocytosis; NI-0101, a toll-like receptor 4 monoclonal antibody; NI-1201, a monoclonal antibody intended to interact with IL-6 receptor to suppress Interleukin-6 (IL-6) driven inflammation; and others. The company has partnership with various pharmaceutical companies, to develop monoclonal and bispecific antibodies. It has a presence in Geneva and Basel, Switzerland. NovImmune is headquartered in Geneva, Switzerland.

NovImmune SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
NovImmune SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
NovImmune SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
NovImmune SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
NovImmune SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
NovImmune SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
NovImmune SA, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
NovImmune Raises USD31 Million in Financing Round 10
Novimmune Raises USD30 Million in Venture Financing 11
NovImmune Raises Additional US$67.3 Million In Series B Financing 12
Partnerships 13
Novimmune and LegoChem Biosciences Enter into Research Agreement 13
Novimmune Enters into Research Agreement with Baxalta 14
Algenics Enters Into Research Collaboration With NovImmune 15
Licensing Agreements 16
Shire Enters into Licensing Agreement with Novimmune 16
Tiziana Life Sciences Enters into Licensing Agreement with Novimmune 17
Genentech Enters into Licensing Agreement with Novimmune 18
Tiziana Life Sciences Enters into Licensing Agreement with Novimmune for Foralumab 19
NovImmune SA – Key Competitors 20
NovImmune SA – Key Employees 21
NovImmune SA – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Corporate Communications 23
Nov 28, 2016: Novimmune appoints Global Head of Project Management 23
Sep 19, 2016: Novimmune broadens Senior Management Team — appointing Chief Financial Officer and Global Head of Quality 24
Product News 25
03/27/2017: Novimmune opens a Branch Office in Basel 25
Product Approvals 26
Jun 06, 2016: Novimmune lead program, NI-0501, granted eligibility for PRIME scheme in Europe 26
Mar 16, 2016: Novimmune’s NI-0501 Granted Breakthrough Therapy Designation by US FDA for Treatment of Patients With Primary Hemophagocytic Lymphohistiocytosis 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
NovImmune SA, Pharmaceuticals & Healthcare, Key Facts 2
NovImmune SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
NovImmune SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
NovImmune SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
NovImmune SA, Deals By Therapy Area, 2011 to YTD 2017 8
NovImmune SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
NovImmune Raises USD31 Million in Financing Round 10
Novimmune Raises USD30 Million in Venture Financing 11
NovImmune Raises Additional US$67.3 Million In Series B Financing 12
Novimmune and LegoChem Biosciences Enter into Research Agreement 13
Novimmune Enters into Research Agreement with Baxalta 14
Algenics Enters Into Research Collaboration With NovImmune 15
Shire Enters into Licensing Agreement with Novimmune 16
Tiziana Life Sciences Enters into Licensing Agreement with Novimmune 17
Genentech Enters into Licensing Agreement with Novimmune 18
Tiziana Life Sciences Enters into Licensing Agreement with Novimmune for Foralumab 19
NovImmune SA, Key Competitors 20
NovImmune SA, Key Employees 21
NovImmune SA, Other Locations 22

★海外企業調査レポート[NovImmune SA-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Trilogy Health Services LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Trilogy Health Services LLC (Trilogy) is a healthcare service provider that offers senior living and long-term healthcare services. The center offers services such as independent living, assisted living, skilled nursing, memory care, rehabilitation, adult day service, respite care, home heal …
  • PTT Public Co Ltd (PTT)-エネルギー分野:企業M&A・提携分析
    Summary PTT Public Company Limited (PTT) is an integrated national oil and gas, and petrochemical company. It operates in oil and natural gas, coal, power, and infrastructure businesses. The company carries out oil and natural gas exploration and production; oil refining; procurement, processing, tr …
  • Weight Watchers International, Inc. (WW):企業の財務・戦略的SWOT分析
    Weight Watchers International, Inc. (WW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • LifeLabs Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary LifeLabsInc (LifeLabs), formerly MDS Diagnostic Services is a laboratory service provider that diagnoses, treats, monitors and prevent diseases in patients. The laboratory's services include clinical studies and services, drug and alcohol screening, employee wellness, hospital lab services, …
  • Malaysia Airlines Berhad:戦略・SWOT・企業財務分析
    Malaysia Airlines Berhad - Strategy, SWOT and Corporate Finance Report Summary Malaysia Airlines Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • AgaMatrix Inc-医療機器分野:企業M&A・提携分析
    Summary AgaMatrix Inc (AgaMatrix) is a medical device company that offers biosensors. The company designs, develops and manufactures diabetes products for pharmaceutical companies. Its products include advanced blood glucose monitoring systems, and diabetes data management systems. AgaMatrix uses pr …
  • G4S plc:企業の戦略・SWOT・財務分析
    G4S plc - Strategy, SWOT and Corporate Finance Report Summary G4S plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Sandoz International GmbH:企業の戦略・SWOT・財務分析
    Sandoz International GmbH - Strategy, SWOT and Corporate Finance Report Summary Sandoz International GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Arena Energy LP:石油・ガス:M&Aディール及び事業提携情報
    Summary Arena Energy Lp (Arena) operates as an oil and gas exploration company. It is engaged in developing and exploring of oil and gas in Gulf of Mexico. It identifies and develops investment opportunities in the Gulf of Mexico Shelf. It is also involved in drilling and off-shore activities. The c …
  • USV Pvt Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary USV Pvt Ltd (USV) is a healthcare company that offers pharmaceutical products. The company’s products include active pharmaceutical ingredients, biosimilars, injectables, ophthalmics, peptides and solid orals. Its biosimilars products comprise PEG-filgrastim, teriparatide, somatropin, filgra …
  • Sumitomo Corporation (8053)-エネルギー分野:企業M&A・提携分析
    Summary Sumitomo Corporation (Sumitomo) is a multifaceted business enterprise. It operates various businesses such as metal products, transportation, construction systems, infrastructure, media, network & lifestyle retail, general products, real estate, financial services, logistics, mineral resourc …
  • GOME Electrical Appliances Holding Limited:企業の戦略・SWOT・財務情報
    GOME Electrical Appliances Holding Limited - Strategy, SWOT and Corporate Finance Report Summary GOME Electrical Appliances Holding Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Second Sight Medical Products Inc (EYES):企業の財務・戦略的SWOT分析
    Summary Second Sight Medical Products Inc (Second Sight) is a medical device company. It develops, manufactures and markets implantable visual prosthetics for blind individuals. The company offers Argus II retinal prosthesis system, a device that restores some functional vision for people suffering …
  • IndusInd Bank Ltd:企業のM&A・事業提携・投資動向
    IndusInd Bank Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's IndusInd Bank Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • NorgesGruppen ASA:企業の戦略的SWOT分析
    NorgesGruppen ASA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • American Shared Hospital Services (AMS):企業の財務・戦略的SWOT分析
    Summary American Shared Hospital Services (ASHS) is a healthcare company that offers medical equipment to hospitals and medical centers. The company offers financial and healthcare tech solutions. Its financing solutions comprise feasibility studies and reimbursement analysis, facilities planning an …
  • Wellmont Health System:企業の戦略的SWOT分析
    Wellmont Health System - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Qliance Medical Management Inc-製薬・医療分野:企業M&A・提携分析
    Summary Qliance Medical Management Inc (QMMI), a subsidiary of Qliance Medical Group is a healthcare service provider that provides primary and preventive care services. The company offers services such as health and wellness, chronic condition management, specialist care coordination, urgent care, …
  • National Aerospace Fasteners Corporation:企業の戦略・SWOT・財務情報
    National Aerospace Fasteners Corporation - Strategy, SWOT and Corporate Finance Report Summary National Aerospace Fasteners Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Saudi Arabian Oil Co:企業の戦略的SWOT分析
    Saudi Arabian Oil Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆